Eris Lifesciences has issued a clarification regarding a recent increase in the trading volume of its shares. The company stated that all material information is disclosed in a timely manner. The increase is purely due to market conditions and is not connected with any undisclosed information or pending announcements by the company. The company continues to adhere to all compliance requirements.
Response to Volume Increase Query
Eris Lifesciences has responded to a query from the exchange regarding a significant increase in its trading volume. The company’s response, dated December 10, 2025, addresses the exchange’s concerns and provides clarity on the matter.
Company Statement
Eris Lifesciences affirmed that all relevant information and announcements that could potentially impact the company’s operations and performance are disclosed promptly and accurately. These disclosures are made in accordance with regulations. The company stated that all relevant information is available in the public domain.
Market-Driven Fluctuation
The company explicitly stated that the recent increase in trading volume is attributable to prevailing market conditions. The increased activity is market-driven, independent of any internal factors, and the company has no control over market fluctuations. The company confirms that the volume change is not a result of insider trading.
Source: BSE